팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2023-03-24 [공지사항] 주식매수선택권 조정에 대하여
      2023-03-21 [공지사항] 큐리언트 정기주주총회에 즈음하여
      2023-03-20 Qurient IR deck 2023 English version
      2023-03-17 주식회사 큐리언트 제15기 사업보고서
      2023-03-17 주식회사 큐리언트 제15기 연결 및 별도 감사보고서
  • Press Release

      2023-03-16 큐리언트, CDK7 표적 항암제 적응증 확장 연구 결과 발표
      2023-03-15 큐리언트, AACR서 면역항암제 1상 면역 활성 결과 발표
      2023-02-03 Qurient Co. Ltd. and TB Alliance Announce Exclusive L...
      2023-02-03 큐리언트, 국제기구에 다제내성 결핵치료제 기술수출
      2023-01-31 큐리언트, ‘면역항암제+키트루다’ 1b/2상 “첫 환자투약”
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file